Side-by-side · Research reference
MOTS-cvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongReviewed16/68 cited
BFDA-ApprovedVerified27/68 cited
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
MOTS-c
Tesamorelin
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Yes — physiological pulsatility preserved
Origin
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
MOTS-c
Tesamorelin
Standard dose
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
2 mg / dayEGRIFTA® (tesamorelin for inje 2010
FDA-approved protocol.
Frequency
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Lower / starter dose
2.5–5 mg / week
Recommended due to limited human data.
1 mg / dayFalutz 2010
1 mg still produces significant IGF-1 elevation.
Evidence basis
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
RCT / FDA-approvedFalutz 2007Falutz 2010
Duration
4–12 weeks (experimental)
Optimal cycle length unknown.
12–52 weeks
VAT returns within months of stopping.
Reconstitution
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Empty stomach, pre-sleep preferred
Half-life
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
03Metabolic / Fat Loss Evidence
Parameter
MOTS-c
Tesamorelin
Primary fat target
Diet-induced / metabolic obesity; systemic fat utilization
Visceral adipose tissue (VAT) — abdominal
Quantified reduction
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
15–20% VAT ↓Falutz 2010
By CT at 26 weeks (Falutz et al., NEJM).
IGF-1 impact
No direct IGF-1 pathway; AMPK-mediated
+66 ng/mL (2 mg dose) · +81% mean elevationFalutz 2007
Effect on lean mass
High dose significantly ↑ lean mass in mice
Modest lean mass preservation / slight increase
Insulin sensitivity
Reversed HFD insulin resistance in 7 days (mice)Lee 2015
Neutral to slight impairment (monitor HbA1c)Clarke 2018
Triglycerides
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
Significant TG reduction noted in Phase 3Falutz 2010
Glucose metabolism
Improved glucose tolerance; GLUT4 upregulationLee 2015
Generally neutral; 4.5% HbA1c elevation riskClarke 2018
Effect reversibility
Unknown — no long-term follow-up data
VAT returns within months of stopping
Key publication
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
MOTS-c
Tesamorelin
Injection site reaction
Mild irritation (reported)
Erythema, pruritus, redness (common)
Fluid retention / Edema
Not reported
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
Glucose intolerance
Improves glucose toleranceLee 2015
HbA1c ↑ in 4.5% vs 1.3% placebo; HbA1c ≥6.5% hazard OR 3.3Clarke 2018
Cardiovascular
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
—
Cancer risk
Contradictory data — some models suggest pro-proliferative effects
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
CNS / Neurological
Insomnia, headache (anecdotal reports)
—
GI symptoms
Nausea, stomach discomfort (reported)
Nausea, diarrhea (mild, transient)
Antibody formation
No data (no long-term human trials)
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
Evidence quality
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
—
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
Absolute Contraindications
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
MOTS-c
Tesamorelin
1. Reconstitution
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Injection site
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality